Department of Dermatology, Dresden-Friedrichstadt Hospital, Dresden, Germany.
Int J Dermatol. 2012 Sep;51(9):1019-36. doi: 10.1111/j.1365-4632.2011.05337.x.
Cutaneous T-cell lymphoma (CTCL) is a myeloproliferative disease with pronounced epidermotropism. The major subtypes of CTCL are mycosis fungoides and Sézary syndrome. Survival is dependent on the histological subtype and clinical stage. Early CTCL has a normal life expectancy, therefore early disease recognition and stage adapted treatment might help to ensure a good prognosis.
This is a review of recent advances in CTCL treatment based on literature review.
Skin targeted therapies are useful for patch and limited plaque disease with phototherapy as the cornerstone of such treatments. More advanced disease will benefit from systemic mono- or combined treatments including drug therapy, extracorporeal photopheresis, and radiotherapy. In practice combined treatments may reduce adverse events and improve response rates. For selected younger patients, stem cell transplantation seems a third-line option.
The therapeutic spectrum for CTCL has been advanced during the last years, providing the opportunity of tailored treatment for patients.
皮肤 T 细胞淋巴瘤（CTCL）是一种具有明显亲表皮性的髓系增殖性疾病。CTCL 的主要亚型包括蕈样真菌病和 Sezary 综合征。存活率取决于组织学亚型和临床分期。早期 CTCL 的预期寿命正常，因此早期识别疾病并进行适应临床分期的治疗可能有助于确保良好的预后。
这是一篇基于文献回顾的 CTCL 治疗新进展的综述。
皮肤靶向治疗对斑片和局限性斑块疾病有效，光疗是此类治疗的基石。更严重的疾病将受益于全身性单一或联合治疗，包括药物治疗、体外光化学疗法和放射疗法。在实践中，联合治疗可能会降低不良反应发生率并提高缓解率。对于选择的年轻患者，干细胞移植似乎是三线治疗选择。
近年来，CTCL 的治疗范围已经扩大，为患者提供了量身定制的治疗机会。
